Holen Sie sich die Stockscreener-App
0.90
0.13%
-0.0012
Biodexa Pharmaceuticals Plc Adr Aktie (BDRX) Neueste Nachrichten
Biodexa Pharmaceuticals Announces ADR Ratio Change Effective July 31, 2025 - TipRanks
Biodexa Pharmaceuticals Announces Reverse ADR Split to Regain Nasdaq Compliance - AInvest
Biodexa Pharmaceuticals PLC Announces ADR Ratio Change Effective July 31, 2025 - Nasdaq
Biodexa Pharmaceuticals to implement 1:10 ADR ratio change - Investing.com
Biodexa Pharmaceuticals PLC Announces ADR Ratio Change from 1:10 to 1:100,000. - AInvest
MFS Extends Deadline for Liquidity Event for MFS Investment Grade Municipal Trust - AInvest
ADR Ratio Change - GlobeNewswire
Biodexa Plans Major ADR Restructuring: 1:10 Reverse Split to Meet Nasdaq Requirements - Stock Titan
Biodexa files European clinical trial application for FAP treatment By Investing.com - Investing.com India
Biodexa files European clinical trial application for FAP treatment - Investing.com
Biodexa's $20M-Backed Phase 3 Trial for Rare Cancer Prevention Drug Expands to Europe - Stock Titan
SMX (Security Matters) Plc (SMX) Stock: Navigating Drops and Gains - investchronicle.com
Company’s Banking Stock: Dissecting a 60.04% Quarterly Revenue Decline Amid Growth - investchronicle.com
Biodexa Pharmaceuticals Secures 100% Shareholder Approval for Key Corporate Decisions at AGM - Stock Titan
Biodexa's $20M-Backed Phase 3 Trial for Rare Genetic Disease FAP Begins Patient Enrollment - Stock Titan
Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) - GlobeNewswire
Biodexa enrolls first patient in type 1 diabetes drug trial - Investing.com
Biodexa Pharmaceuticals changes share nominal value By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals changes share nominal value - Investing.com
Biodexa shareholders approve all resolutions at general meeting By Investing.com - Investing.com India
Biodexa shareholders approve all resolutions at general meeting - Investing.com
Phase 2 Trial Begins: Biodexa's Breakthrough Type 1 Diabetes Drug Shows Promise in Human Cells - Stock Titan
Biodexa secures additional $3M for cancer drug trial By Investing.com - Investing.com India
BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - Stock Titan
Biodexa secures additional $3M for cancer drug trial - Investing.com
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here - sharewise
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Nasdaq
Biodexa Pharmaceuticals adjusts warrant exercise price - Investing.com
Biodexa Pharmaceuticals adjusts warrant exercise price By Investing.com - Investing.com India
Biodexa gains orphan drug status in EU for colon disease treatment - Investing.com
Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP - GlobeNewswire
Result of General Meeting - GlobeNewswire
What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock - MSN
Biodexa Shareholders to Vote on Strategic Share Subdivision Plan: Key Meeting Details Revealed - Stock Titan
Biodexa Annual Results Reveal Clinical-Stage Pipeline Expansion Strategy - Stock Titan
Biodexa Pharmaceuticals advances FAP treatment trial By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals advances FAP treatment trial - Investing.com India
With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter - BioSpace
Biodexa gets FDA nod for Phase 3 eRapa study in FAP - Investing.com India
Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday - Yahoo Finance
Biodexa selects Precision as CRO for eRapa Phase 3 study in Europe - Investing.com
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - Barchart
Biodexa Pharmaceuticals Plc ADR [BDRX] Is Currently 31.94 above its 200 Period Moving Avg: What Does This Mean? - The DBT News
why Teva- Pharmaceutical Industries Ltd. ADR [TEVA] is a Good Choice for Investors After New Price Target of $24.71 - The DBT News
Palantir Technologies Inc [PLTR] Is Currently -0.39 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Biodexa Pharmaceuticals Plc ADR (BDRX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Hesai Group ADR (HSAI) Shares Up Despite Recent Market Volatility - The News Heater
Biodexa Pharmaceuticals Plc ADR (BDRX) vs. Its Peers: A Comparison - The News Heater
Omega Therapeutics Inc (OMGA) Stock: A SWOT Analysis - The News Heater
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis - GlobeNewswire
AES Corp (AES) Shares Down Despite Recent Market Volatility - The News Heater
Altus Power Inc (AMPS) vs. Its Peers: A Comparison - The News Heater
Skechers (SKX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance
Biodexa Pharmaceuticals regains Nasdaq compliance - Investing.com
Biodexa Announces Successful Appeal of Nasdaq Delisting - Stock Titan
BDRX Stock Price and Chart — NASDAQ:BDRX - TradingView
4.79%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):